Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. Edwards Lifesciences affirms guidance, ups stake in CardioKinetix, lures Medtronic exec

Edwards Lifesciences today affirmed its outlook for the rest of this year and revealed its guidance for 2015, also saying it increased its stake in CardioKinetix and lured a top executive away from rival Medtronic.

Irvine, Calif.-based Edwards said it still expects to report adjusted earnings per share of of $3.33 to $3.39 on sales of of $3.33 to $3.39 for 2014. Adjusted EPS next year are expected to be $3.90 to $4.10 on sales of $2.3 billion to $2.5 billion, the company said. Read more

2. BD prices $6.2B bond issue for CareFusion buy

Becton Dickinson priced a debt offering yesterday that it plans to use to consummate its $12.2 billion offer for CareFusion.

The offering entails 5 sets of senior unsecured bonds worth a collective $6.2 billion. Read more

1. More positive data for St. Jude Medical’s Optim defib leads

An independent review of long-term data from a trio of registry studies funded by St. Jude Medical for defibrillator leads coated with its Optim insulation showed that the devices are largely free of problems that led to a recall for their Riata predecessors.

The study looked at data from registries St. Jude set up between 2006 and 2009 to follow some 10,800 patients implanted with the St. Paul., Minn.-based company’s Durata DF4, Durata DF1 and Riata ST Optim leads. Read more